Nursing Diagnosis Care Plan for Congestive Heart Failure: A Comprehensive Guide

Introduction

Congestive Heart Failure (CHF) is a prevalent and intricate clinical syndrome arising from structural or functional heart disorders. This condition impairs the heart’s ability to effectively fill with or eject blood, hindering systemic circulation and the body’s metabolic demands. Often stemming from various underlying diseases, CHF manifests primarily through left ventricular dysfunction in most patients. Common symptoms include dyspnea, fatigue, reduced exercise capacity, and fluid retention, clinically evident as pulmonary and peripheral edema.[1]

Heart failure due to left ventricular issues is categorized by left ventricular ejection fraction (LVEF) into two main types: Heart Failure with reduced Ejection Fraction (HFrEF), where LVEF is 40% or less, and Heart Failure with preserved Ejection Fraction (HFpEF), where LVEF is greater than 40%.[2] Effective nursing care is crucial in managing CHF, focusing on alleviating symptoms, improving quality of life, and preventing hospital readmissions. This guide provides a comprehensive overview of nursing diagnoses and care plans for patients with congestive heart failure.

Understanding Congestive Heart Failure

Pathophysiology of Heart Failure

Heart failure is not a disease itself but a syndrome resulting from the heart’s inability to pump blood efficiently to meet the body’s needs. This can occur due to systolic dysfunction (HFrEF) or diastolic dysfunction (HFpEF).

• Heart Failure with Reduced Ejection Fraction (HFrEF): Characterized by the heart muscle’s weakened ability to contract effectively. Common causes include ischemic heart disease, dilated cardiomyopathy, hypertension, and valve disorders. The reduced contractility leads to decreased cardiac output, causing blood to back up into the pulmonary and systemic circulation.
• Heart Failure with Preserved Ejection Fraction (HFpEF): Occurs when the heart muscle becomes stiff and loses its ability to relax properly. Conditions like hypertension, hypertrophic cardiomyopathy, and restrictive cardiomyopathy are typical causes. While the ejection fraction is preserved, the impaired relaxation hinders ventricular filling, leading to increased pressure and symptoms of heart failure.

Clinical Signs and Symptoms

Patients with CHF present with a range of symptoms related to fluid overload and reduced cardiac output.

Fluid Overload Symptoms:

• Dyspnea: Shortness of breath, initially on exertion and progressing to rest.
• Orthopnea: Difficulty breathing when lying flat, often relieved by sitting up or using pillows.
• Paroxysmal Nocturnal Dyspnea (PND): Sudden episodes of severe shortness of breath at night that awaken the patient.
• Edema: Swelling in the ankles, legs, abdomen (ascites), and sacral area.
• Right Upper Quadrant Pain: Due to liver congestion.
• Abdominal Distension: From ascites and bowel edema.

Reduced Cardiac Output Symptoms:

• Fatigue: Unusual tiredness and weakness, especially with activity.
• Weakness: General feeling of lack of strength.
• Dizziness and Lightheadedness: Due to decreased blood flow to the brain.
• Exercise Intolerance: Inability to perform usual physical activities.
• Cool and Clammy Skin: Reflecting poor peripheral perfusion.
• Tachycardia: Increased heart rate as the body tries to compensate for reduced output.

Risk Factors and Causes of Heart Failure

CHF can be triggered or exacerbated by various factors. Identifying these is crucial for both prevention and management.

Common Causes:

• Coronary Artery Disease (CAD): Reduced blood flow to the heart muscle, often leading to myocardial infarction and subsequent heart failure.
• Hypertension: Chronic high blood pressure forces the heart to work harder, eventually leading to weakening and failure.
• Valvular Heart Disease: Conditions affecting heart valves, such as stenosis or regurgitation, strain the heart.
• Cardiomyopathy: Diseases of the heart muscle itself, including dilated, hypertrophic, and restrictive types.
• Myocarditis: Inflammation of the heart muscle, often due to viral infections.

Risk Factors:

• Age: Risk increases with age.
• Family History of Heart Disease: Genetic predisposition.
• Diabetes Mellitus: High blood sugar levels damage blood vessels and the heart.
• Obesity: Excess weight increases the heart’s workload.
• Smoking: Damages blood vessels and increases heart rate and blood pressure.
• Alcohol Abuse: Excessive alcohol consumption can weaken the heart muscle.
• Atrial Fibrillation: Irregular heart rhythm that can lead to heart failure.
• Thyroid Disorders: Both hyperthyroidism and hypothyroidism can impact heart function.
• Congenital Heart Defects: Structural abnormalities present at birth.
• Anemia: Reduced oxygen-carrying capacity of the blood forces the heart to pump harder.
• Sleep Apnea: Disruptions in breathing during sleep can strain the cardiovascular system.

Key Nursing Diagnoses for Congestive Heart Failure

Nursing diagnoses for CHF patients focus on the physiological and psychological challenges they face. Common nursing diagnoses include:

• Decreased Cardiac Output
• Excess Fluid Volume
• Impaired Gas Exchange
• Activity Intolerance
• Fatigue
• Anxiety
• Risk for Impaired Skin Integrity
• Ineffective Tissue Perfusion
• Ineffective Breathing Pattern

Nursing Care Plan Strategies for Congestive Heart Failure

For each nursing diagnosis, a tailored care plan is essential. Below are common nursing diagnoses for CHF patients with corresponding nursing interventions and expected outcomes.

1. Decreased Cardiac Output

Related Factors: Altered contractility, altered heart rate/rhythm, structural abnormalities.

Assessment Findings:

• Hypotension or hypertension
• Tachycardia or bradycardia, arrhythmias
• Weak peripheral pulses, delayed capillary refill
• Cool, clammy skin, pallor or cyanosis
• Oliguria
• Fatigue, weakness, dizziness
• Chest pain
• S3 or S4 heart sounds
• Decreased level of consciousness

Nursing Interventions:

• Monitor vital signs frequently: Pay close attention to heart rate, blood pressure, and rhythm.
• Assess peripheral pulses and capillary refill: Evaluate tissue perfusion.
• Auscultate heart sounds: Identify abnormal sounds like S3, S4, murmurs.
• Administer medications as prescribed: Including diuretics, ACE inhibitors, beta-blockers, digoxin, and vasodilators to improve contractility, reduce afterload, and control heart rate.
• Monitor ECG: Detect arrhythmias and conduction abnormalities.
• Elevate legs when sitting: To promote venous return.
• Provide rest periods: Reduce cardiac workload.
• Monitor fluid balance: Strict intake and output, daily weights.
• Limit sodium and fluid intake: Reduce fluid overload and cardiac workload.
• Educate patient on medication regimen and importance of adherence.

Expected Outcomes:

• Patient will maintain adequate cardiac output as evidenced by stable vital signs, strong peripheral pulses, and absence of chest pain.
• Patient will demonstrate understanding of medications and lifestyle modifications to support cardiac function.

2. Excess Fluid Volume

Related Factors: Decreased cardiac output, sodium and water retention, impaired venous return.

Assessment Findings:

• Weight gain
• Peripheral edema (ankles, legs, sacral area)
• Pulmonary edema (crackles/rales in lungs)
• Jugular vein distension (JVD)
• Shortness of breath, orthopnea, PND
• Increased blood pressure
• Decreased urine output
• Ascites

Nursing Interventions:

• Monitor daily weight: Report gains of 2 lbs or more in one day or 5 lbs in a week.
• Assess for edema: Location, severity, and pitting.
• Auscultate lung sounds: Monitor for crackles/rales indicative of pulmonary edema.
• Measure abdominal girth: Assess for ascites.
• Monitor intake and output: Strict fluid balance monitoring.
• Administer diuretics as prescribed: To promote fluid excretion.
• Restrict sodium intake: Typically to 2-3 grams per day.
• Restrict fluid intake: Usually to 1.5-2 liters per day as ordered.
• Elevate legs when sitting or lying down: Promote venous return and reduce edema.
• Educate patient about fluid and sodium restrictions and the importance of daily weight monitoring.

Expected Outcomes:

• Patient will achieve and maintain fluid balance as evidenced by stable weight, reduced edema, clear lung sounds, and balanced intake and output.
• Patient will adhere to prescribed dietary and fluid restrictions.

3. Impaired Gas Exchange

Related Factors: Pulmonary congestion, alveolar-capillary membrane changes, decreased cardiac output.

Assessment Findings:

• Dyspnea, orthopnea, PND
• Tachypnea
• Crackles or wheezes on auscultation
• Cough, possibly with frothy sputum
• Cyanosis
• Restlessness, anxiety, confusion
• Decreased oxygen saturation (SpO2)
• Abnormal arterial blood gases (ABGs)

Nursing Interventions:

• Monitor respiratory rate, depth, and effort: Assess for signs of respiratory distress.
• Auscultate lung sounds: Identify adventitious sounds.
• Monitor oxygen saturation continuously or intermittently: Use pulse oximetry.
• Administer supplemental oxygen as prescribed: Maintain SpO2 as ordered.
• Position patient in high Fowler’s position: Maximize lung expansion.
• Encourage deep breathing and coughing exercises: Promote lung expansion and clear secretions.
• Administer medications as prescribed: Bronchodilators or diuretics if indicated.
• Monitor ABGs: Evaluate gas exchange effectiveness.
• Reduce fluid overload: As excess fluid contributes to pulmonary congestion.

Expected Outcomes:

• Patient will demonstrate improved gas exchange as evidenced by normal respiratory rate, clear breath sounds, SpO2 within acceptable limits, and absence of cyanosis.
• Patient will report reduced dyspnea and improved comfort with breathing.

4. Activity Intolerance

Related Factors: Decreased cardiac output, fatigue, dyspnea, imbalance between oxygen supply and demand.

Assessment Findings:

• Reports of fatigue or weakness
• Dyspnea on exertion
• Increased heart rate and respiratory rate with activity
• Weakness or dizziness with activity
• ECG changes indicating ischemia with activity

Nursing Interventions:

• Assess patient’s activity tolerance: Determine limitations and contributing factors.
• Monitor vital signs before, during, and after activity: Assess response to activity.
• Plan activities with rest periods: Balance activity and rest to reduce fatigue.
• Assist with activities of daily living (ADLs) as needed: Conserve patient’s energy.
• Encourage participation in cardiac rehabilitation program: Gradually increase activity level under supervision.
• Educate patient on energy conservation techniques: Pacing activities, prioritizing tasks.
• Promote mild to moderate exercise as tolerated: Improve cardiovascular fitness.
• Ensure adequate rest and sleep: Reduce fatigue.

Expected Outcomes:

• Patient will demonstrate increased activity tolerance as evidenced by ability to perform ADLs with less fatigue and dyspnea.
• Patient will participate in a progressive activity program to improve functional capacity.

5. Fatigue

Related Factors: Decreased cardiac output, altered metabolic state, anemia, sleep disturbance, emotional distress.

Assessment Findings:

• Verbal reports of overwhelming lack of energy
• Inability to maintain usual routines
• Increased physical and emotional complaints
• Lethargy, decreased motivation
• Difficulty concentrating
• Irritability

Nursing Interventions:

• Assess and document fatigue levels: Use fatigue scales if appropriate.
• Identify contributing factors: Anemia, sleep disorders, medications, depression.
• Encourage rest periods: Schedule rest periods throughout the day.
• Promote adequate sleep hygiene: Consistent sleep schedule, comfortable environment.
• Optimize nutritional status: Ensure adequate intake of nutrients.
• Manage anemia if present: Administer iron or erythropoietin as prescribed.
• Encourage mild to moderate exercise: Improve energy levels over time.
• Address emotional distress: Provide emotional support, refer to counseling if needed.
• Educate patient on energy conservation techniques.

Expected Outcomes:

• Patient will report a decrease in fatigue levels.
• Patient will demonstrate improved ability to participate in desired activities.
• Patient will implement energy conservation techniques effectively.

6. Anxiety

Related Factors: Dyspnea, fear of death, changes in health status, social isolation, financial concerns.

Assessment Findings:

• Verbal reports of anxiety, fear, worry
• Restlessness, irritability
• Increased heart rate, respiratory rate, blood pressure
• Trembling, diaphoresis
• Insomnia
• Difficulty concentrating

Nursing Interventions:

• Assess patient’s level of anxiety: Use anxiety scales if appropriate.
• Provide calm and reassuring environment: Reduce environmental stressors.
• Encourage verbalization of feelings: Provide active listening and empathy.
• Provide accurate and honest information: Address misconceptions and fears.
• Teach relaxation techniques: Deep breathing, guided imagery, meditation.
• Administer anti-anxiety medications as prescribed: If non-pharmacological measures are insufficient.
• Ensure patient understands their condition, treatment plan, and prognosis.
• Facilitate social support: Connect with family, friends, support groups.

Expected Outcomes:

• Patient will report a reduction in anxiety levels.
• Patient will demonstrate effective coping mechanisms to manage anxiety.
• Patient will express feelings and concerns openly.

7. Risk for Impaired Skin Integrity

Risk Factors: Edema, poor tissue perfusion, immobility, friction and shear.

Assessment Findings:

• Edema
• Decreased mobility
• Dry, fragile skin
• Presence of pressure points
• Prolonged pressure on bony prominences
• Inadequate nutrition

Nursing Interventions:

• Assess skin regularly: Pay attention to pressure points, edema areas.
• Maintain skin hygiene: Keep skin clean and dry.
• Apply moisturizing lotions: Prevent dryness and cracking.
• Reposition patient frequently: At least every 2 hours, more often if needed.
• Use pressure-redistribution devices: Special mattresses, cushions.
• Elevate edematous extremities: Reduce edema and improve circulation.
• Protect skin from friction and shear: Use lift sheets for repositioning.
• Ensure adequate nutrition and hydration: Support skin health.
• Educate patient and caregivers on skin care and pressure ulcer prevention.

Expected Outcomes:

• Patient will maintain intact skin integrity throughout hospitalization and care.
• Patient will demonstrate understanding of measures to prevent skin breakdown.

8. Ineffective Tissue Perfusion

Related Factors: Decreased cardiac output, hypovolemia, vasoconstriction, impaired blood flow.

Assessment Findings:

• Cool, clammy skin
• Pallor or cyanosis
• Weak or absent peripheral pulses
• Delayed capillary refill (>3 seconds)
• Pain (e.g., chest pain, leg pain with activity)
• Changes in mental status
• Decreased urine output

Nursing Interventions:

• Monitor peripheral pulses, skin color and temperature, and capillary refill: Assess perfusion status.
• Monitor vital signs: Hypotension can compromise tissue perfusion.
• Administer medications as prescribed: Vasodilators, antiplatelets, anticoagulants to improve blood flow.
• Elevate legs (if appropriate): Improve venous return to the heart.
• Avoid constricting clothing or positions: Promote circulation.
• Encourage regular, gentle exercise within tolerance: Improve circulation.
• Maintain adequate hydration: Support blood volume and viscosity.
• Educate patient on risk factors for impaired perfusion and strategies to improve circulation.

Expected Outcomes:

• Patient will demonstrate adequate tissue perfusion as evidenced by warm and dry skin, palpable peripheral pulses, and timely capillary refill.
• Patient will report reduced symptoms related to poor perfusion, such as pain or dizziness.

9. Ineffective Breathing Pattern

Related Factors: Pulmonary congestion, reduced lung expansion, fatigue, anxiety.

Assessment Findings:

• Tachypnea or bradypnea
• Shallow respirations
• Use of accessory muscles
• Orthopnea, PND
• Dyspnea
• Altered chest excursion
• Nasal flaring, grunting

Nursing Interventions:

• Assess respiratory rate, depth, and pattern: Identify breathing abnormalities.
• Auscultate lung sounds: Detect adventitious sounds.
• Position patient to maximize lung expansion: High Fowler’s position.
• Encourage deep breathing and coughing exercises: Improve ventilation and clear secretions.
• Administer oxygen therapy as prescribed: Support oxygenation.
• Monitor oxygen saturation: Evaluate effectiveness of oxygen therapy and breathing.
• Provide rest periods to reduce fatigue: Improve respiratory effort.
• Manage anxiety: Anxiety can exacerbate breathing difficulties.
• Educate patient on proper breathing techniques and positioning.

Expected Outcomes:

• Patient will demonstrate an effective breathing pattern as evidenced by normal respiratory rate and depth, unlabored respirations, and absence of dyspnea at rest.
• Patient will utilize effective breathing techniques.

Alt text: Chest X-ray showing cardiomegaly and pulmonary congestion, indicative of congestive heart failure.

Medical Management and Nursing Collaboration

Medical management of CHF aims to reduce symptoms, improve quality of life, and prolong survival. Nurses play a critical role in collaborating with the medical team to implement and monitor the treatment plan.

Common Medical Treatments:

• Diuretics: Reduce fluid overload (e.g., furosemide, hydrochlorothiazide).
• ACE Inhibitors or Angiotensin Receptor Blockers (ARBs): Reduce afterload and improve ventricular function (e.g., enalapril, valsartan).
• Beta-Blockers: Reduce heart rate and blood pressure, improve long-term outcomes (e.g., metoprolol, carvedilol).
• Digoxin: Increases contractility and slows heart rate.
• Aldosterone Antagonists: Reduce sodium and water retention, especially in severe heart failure (e.g., spironolactone, eplerenone).
• Angiotensin Receptor-Neprilysin Inhibitors (ARNIs): Combine ARB with neprilysin inhibitor to improve outcomes in HFrEF (e.g., sacubitril/valsartan).
• Hydralazine and Isosorbide Dinitrate: Vasodilators, particularly beneficial in African Americans with HFrEF.
• Device Therapy: Implantable cardioverter-defibrillators (ICDs) to prevent sudden cardiac death and cardiac resynchronization therapy (CRT) to improve heart rhythm and function.
• Ventricular Assist Devices (VADs) and Heart Transplantation: For advanced heart failure.

Nursing Roles in Medical Management:

• Medication Administration and Monitoring: Ensure timely and accurate medication administration, monitor for therapeutic and adverse effects.
• Patient Assessment: Regularly assess patient’s response to medications and treatments, reporting any changes to the physician.
• Coordination of Care: Collaborate with physicians, pharmacists, and other healthcare professionals to optimize patient care.
• Patient Education: Educate patients about their medications, potential side effects, and the importance of adherence.

Patient Education and Discharge Planning

Patient education is a cornerstone of CHF management. Nurses are instrumental in preparing patients for self-management at home and ensuring a smooth transition from hospital to home.

Key Education Points:

• Medication Management: Names, dosages, frequency, purpose, and side effects of all medications. Importance of adherence and not stopping medications without consulting the physician.
• Dietary Modifications: Sodium restriction (2-3 grams/day), fluid restriction (1.5-2 liters/day), heart-healthy diet.
• Daily Weight Monitoring: How to weigh themselves daily, when to report weight changes.
• Symptom Monitoring: Recognizing signs and symptoms of worsening heart failure (increased shortness of breath, edema, fatigue, dizziness) and when to seek medical attention.
• Activity and Exercise Recommendations: Importance of regular, moderate exercise, pacing activities, and avoiding overexertion.
• Smoking Cessation and Alcohol Moderation: If applicable, provide resources and support for quitting smoking and reducing alcohol intake.
• Follow-up Appointments: Importance of keeping all scheduled appointments with healthcare providers.

Discharge Planning Components:

• Medication Reconciliation: Ensure patient has all necessary medications and prescriptions upon discharge.
• Home Health Referrals: Arrange for home health nursing if needed for ongoing monitoring and support.
• Community Resources: Provide information on support groups, cardiac rehabilitation programs, and other community resources.
• Emergency Plan: Educate patient and family on what to do in case of worsening symptoms or emergencies.
• Written Discharge Instructions: Provide clear, written instructions on medications, diet, activity, follow-up appointments, and emergency contact information.

Conclusion

Effective nursing care is paramount in managing congestive heart failure. By utilizing comprehensive nursing diagnoses and tailored care plans, nurses can significantly improve patient outcomes, alleviate symptoms, enhance quality of life, and reduce hospital readmissions. A focus on patient education, medication management, symptom monitoring, and lifestyle modifications empowers patients to actively participate in their care and live healthier lives with CHF. This guide serves as a foundational resource for nurses in providing holistic and evidence-based care for individuals living with congestive heart failure.

References

1.Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW., ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 03;145(18):e895-e1032. [PubMed: 35363499]

2.Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78. [PMC free article: PMC4868779] [PubMed: 26935038]

3.CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 04;316(23):1429-35. [PubMed: 2883575]

4.Lind L, Ingelsson M, Sundstrom J, Ärnlöv J. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Heart. 2021 Sep;8(2) [PMC free article: PMC8438838] [PubMed: 34518286]

5.Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019 Nov 19;9(1):17022. [PMC free article: PMC6863880] [PubMed: 31745178]

6.Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circ J. 2021 Oct;51(10):797-836. [PMC free article: PMC8484993] [PubMed: 34327881]

7.Rezkalla SH, Kloner RA. Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics. Trends Cardiovasc Med. 2021 Apr;31(3):163-169. [PMC free article: PMC7965406] [PubMed: 33383171]

8.Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 15;121(7):819-837. [PubMed: 28912185]

9.Shams P, Ahmed I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Cardiac Amyloidosis. [PubMed: 35593829]

10.Brown KN, Pendela VS, Ahmed I, Diaz RR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Restrictive Cardiomyopathy. [PubMed: 30725919]

11.Matta AG, Carrié D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med Sci Monit. 2023 Mar 06;29:e939020. [PMC free article: PMC9999670] [PubMed: 36872594]

12.Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr;39:100990. [PMC free article: PMC8913320] [PubMed: 35281752]

13.Ahmad SA, Brito D, Khalid N, Ibrahim MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Takotsubo Cardiomyopathy. [PubMed: 28613549]

14.DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CSP, Hsich E. Heart Failure Subtypes and Cardiomyopathies in Women. Circ Res. 2022 Feb 18;130(4):436-454. [PMC free article: PMC10361647] [PubMed: 35175847]

15.Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013 Nov 12;62(20):1845-54. [PubMed: 23850914]

16.Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, Piepoli MF. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):46-51. [PMC free article: PMC7691623] [PubMed: 33238736]

17.Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. [PMC free article: PMC10040794] [PubMed: 36993998]

18.Kim DY, Kim SH, Ryu KH. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019 Sep;49(9):808-817. [PMC free article: PMC6713829] [PubMed: 31456374]

19.Anakwue RC, Onwubere BJ, Anisiuba BC, Ikeh VO, Mbah A, Ike SO. Congestive heart failure in subjects with thyrotoxicosis in a black community. Vasc Health Risk Manag. 2010 Aug 09;6:473-7. [PMC free article: PMC2922308] [PubMed: 20730063]

20.Schoenenberger AW, Schoenenberger-Berzins R, der Maur CA, Suter PM, Vergopoulos A, Erne P. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. Clin Res Cardiol. 2012 Mar;101(3):159-64. [PubMed: 22057652]

21.DiNicolantonio JJ, Liu J, O’Keefe JH. Thiamine and Cardiovascular Disease: A Literature Review. Prog Cardiovasc Dis. 2018 May-Jun;61(1):27-32. [PubMed: 29360523]

22.Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016 Aug 02;68(5):473-482. [PubMed: 27470455]

23.Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014 Jul;8(3):308-15. [PMC free article: PMC4160726] [PubMed: 25221635]

24.Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 03;141(9):e139-e596. [PubMed: 31992061]

25.Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A. [PubMed: 8376698]

26.Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 07;135(10):e146-e603. [PMC free article: PMC5408160] [PubMed: 28122885]

27.Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F, Oguz A, Kruger IM, Diaz R, Yusoff K, Mony P, Chifamba J, Yeates K, Kelishadi R, Yusufali A, Khatib R, Rahman O, Zatonska K, Iqbal R, Wei L, Bo H, Rosengren A, Kaur M, Mohan V, Lear SA, Teo KK, Leong D, O’Donnell M, McKee M, Dagenais G. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 07;395(10226):795-808. [PMC free article: PMC8006904] [PubMed: 31492503]

28.Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006 Jan 28;367(9507):356-67. [PubMed: 16443044]

29.Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. [PubMed: 22227365]

30.Ait Mou Y, Bollensdorff C, Cazorla O, Magdi Y, de Tombe PP. Exploring cardiac biophysical properties. Glob Cardiol Sci Pract. 2015;2015:10. [PMC free article: PMC4448074] [PubMed: 26779498]

31.Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. [PMC free article: PMC9553007] [PubMed: 36237903]

32.Prausmüller S, Arfsten H, Spinka G, Freitag C, Bartko PE, Goliasch G, Strunk G, Pavo N, Hülsmann M. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. J Am Heart Assoc. 2020 Jun 02;9(11):e015071. [PMC free article: PMC7428996] [PubMed: 32427034]

33.Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800-810. [PMC free article: PMC8837825] [PubMed: 33004114]

34.Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):245-257. [PMC free article: PMC6899218] [PubMed: 31202759]

35.Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35. [PMC free article: PMC4654630] [PubMed: 26250359]

36.Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 Jul;19(7):821-836. [PMC free article: PMC5734941] [PubMed: 28560717]

37.King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. Am Fam Physician. 2012 Jun 15;85(12):1161-8. [PubMed: 22962896]

38.Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja F, Sabbah HN, Goldstein S. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J. 1999 Dec;138(6 Pt 1):1133-9. [PubMed: 10577445]

39.Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF, Califf RM, Gheorghiade M., OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005 May 17;111(19):2454-60. [PubMed: 15867182]

40.Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73. [PubMed: 22104551]

41.Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, Køber L, Prescott MF, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 Feb;13(2):e006541. [PubMed: 32065760]

42.Hacker M, Hoyer X, Kupzyk S, La Fougere C, Kois J, Stempfle HU, Tiling R, Hahn K, Störk S. Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging. 2006 Jun-Aug;22(3-4):407-16. [PubMed: 16328851]

43.Jain S, Londono FJ, Segers P, Gillebert TC, De Buyzere M, Chirinos JA. MRI Assessment of Diastolic and Systolic Intraventricular Pressure Gradients in Heart Failure. Curr Heart Fail Rep. 2016 Feb;13(1):37-46. [PubMed: 26780916]

44.Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013 Aug 30;113(6):660-75. [PubMed: 23989711]

45.Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA., American Heart Association Get With the Guidelines-Heart Failure Program. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32. [PubMed: 20123668]

46.Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O’Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW., VICTORIA Study Group. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021 Nov 16;10(22):e021094. [PMC free article: PMC8751950] [PubMed: 34743540]

47.Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM., VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. [PubMed: 32222134]

48.Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000 Dec;140(6):840-7. [PubMed: 11099986]

49.Rider I, Sorensen M, Brady WJ, Gottlieb M, Benson S, Koyfman A, Long B. Disposition of acute decompensated heart failure from the emergency department: An evidence-based review. Am J Emerg Med. 2021 Dec;50:459-465. [PubMed: 34500232]